![fauci dossier fauci dossier](https://www.bibliotecapleyades.net/imagenes_ciencia4/coronavirus401_01_small.jpg)
Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Their application, updated in 2007, ultimately issued as U.S.
![fauci dossier fauci dossier](https://stateofthenation.co/wp-content/uploads/2021/07/Screen-Shot-2021-07-11-at-6.36.10-AM-227x300.png)
This legality did not deter CDC in their efforts. 60/206,537, filed May 21, 2000Īgainst this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on Apthey sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 19 before SARS was ever detected in humans.ġ U.S.
![fauci dossier fauci dossier](https://constitutionwatch.com.au/wp-content/uploads/Screen-Shot-2021-04-19-at-10.22.28-am-768x427.png)
![fauci dossier fauci dossier](http://www.hillmanweb.com/archive/rare/fauci22s.jpg)
In the first public record of the claims, they sought to patent a means of producing, “an infectious, replication defective, coronavirus.” This work was supported by the NIH grant referenced above and GM63228. Patent 7,279,372 for a method of producing recombinant coronavirus. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. On Ap– the Spring before the first SARS outbreak in Asia – Christopher M. “Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.”2 Baric published what he reported to be the full length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.1 In one of the several papers derived from work sponsored by this grant, Dr. Anthony Fauci’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. The National Institute of Health’s grant AI23946-08 issued to Dr. Since that time, on a weekly basis, we have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC),the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, many other research institutions, and their commercial affiliations. In our 2003-2004 Global Technology Assessment: Vector Weaponization M♼AM highlighted China’s growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Over the past two decades, my company – M♼AM – has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC).